GSK (NYSE:GSK) Receives Neutral Rating from Citigroup

Posted by Geri Gentry on Jul 24th, 2026

GSK (NYSE:GSK – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Citigroup in a research note issued to investors on Friday,Benzinga reports.

GSK has been the subject of several other reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a report on Thursday, July 9th. Weiss Ratings cut GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th. HSBC raised GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. Finally, Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Hold” and an average target price of $53.00.

Read Our Latest Analysis on GSK

GSK Stock Up 0.0%

GSK stock opened at $50.78 on Friday. The stock has a market capitalization of $102.71 billion, a PE ratio of 13.20, a price-to-earnings-growth ratio of 3.23 and a beta of 0.35. The company has a fifty day moving average of $51.55 and a 200-day moving average of $53.41. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79. GSK has a one year low of $36.75 and a one year high of $61.69.

Institutional Investors Weigh In On GSK

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Valeo Financial Advisors LLC lifted its position in shares of GSK by 5.5% in the second quarter. Valeo Financial Advisors LLC now owns 10,149 shares of the pharmaceutical company’s stock valued at $532,000 after acquiring an additional 532 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of GSK by 8.0% during the second quarter. GAMMA Investing LLC now owns 11,330 shares of the pharmaceutical company’s stock worth $594,000 after buying an additional 840 shares in the last quarter. Parallel Advisors LLC raised its position in shares of GSK by 17.5% in the first quarter. Parallel Advisors LLC now owns 9,424 shares of the pharmaceutical company’s stock valued at $520,000 after buying an additional 1,405 shares during the last quarter. Arkadios Wealth Advisors raised its holdings in GSK by 0.6% in the 1st quarter. Arkadios Wealth Advisors now owns 108,026 shares of the pharmaceutical company’s stock valued at $5,962,000 after acquiring an additional 647 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of GSK by 67.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,092 shares of the pharmaceutical company’s stock worth $336,000 after purchasing an additional 2,457 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

Positive Sentiment: GSK received FDA approval for Jideytro, its first lung cancer treatment, ahead of the original review deadline, supporting its precision oncology expansion. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Positive Sentiment: The approval strengthens the case for GSK’s recent Nuvalent acquisition, with multiple reports highlighting that the deal is already delivering a commercial win in oncology. GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Positive Sentiment: GSK also said its Specialty Medicines unit is expected to post double-digit growth, driven by newer HIV, respiratory/inflammation, and oncology drugs, which could help offset pressure from older products. Will GSK’s Specialty Medicines Boost Q2 Revenue Growth?
Neutral Sentiment: Separately, GSK is also seeking an EMA label update for Bexsero and reported positive phase II data for Jemperli in rectal cancer, but these updates are earlier-stage and less immediately material than the FDA approval. GSK (LSE:GSK) Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance

GSK Company Profile

(Get Free Report)

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.